Entia Biosciences, Inc. (ERGO)

OTCMKTS · Delayed Price · Currency is USD
0.0003
0.00 (0.00%)
At close: Jan 27, 2026
Market Cap10.22K -97.2%
Revenue (ttm)265.47K -23.5%
Net Income-1.40M
EPS-0.05
Shares Out34.06M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume5,575
Average Volume23,004
Open0.0003
Previous Close0.0003
Day's Range0.0003 - 0.0003
52-Week Range0.0001 - 0.0402
Beta24.65
RSI42.95
Earnings Daten/a

About Entia Biosciences

Entia Biosciences, Inc. engages in the development, production, and distribution of dietary supplements, nutraceuticals, and medical food products in the United States. The company develops ErgoD2, a pharmaceutical grade organic compound for the improvement of iron homeostasis and mitigation of iron-related disorders presenting in anemia, chronic kidney disease, and select neurodegenerative diseases. It is also involved in the discovery, scientific evaluation, and marketing of natural formulations that can be used in medical food, nutraceutical... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2007
Employees 7
Stock Exchange OTCMKTS
Ticker Symbol ERGO
Full Company Profile

Financial Performance

In 2016, Entia Biosciences's revenue was $265,466, a decrease of -23.48% compared to the previous year's $346,910. Losses were -$1.40 million, -38.24% less than in 2015.

Financial Statements